Head-to-head evidence
HRC0202 vs Trovocabtagene autoleucel (C-CAR088)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA · full Multiple Myeloma pipeline
HRC0202
Developed by Hrain Biotechnology Co., Ltd.
NCT04003168 · Phase 1 · status unknown
This is a small, single-arm, open-label safety study with no control group, so it cannot show whether the therapy works better than an alternative. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The published report covers seven treated patients, fewer than the study's listed enrollment.
Trovocabtagene autoleucel (C-CAR088)
Developed by AbelZeta Pharma, Inc.
NCT03751293 · Phase 1 · status unknown
This is a very small, open-label, single-arm safety study of a cell therapy with no comparator group and no blinding, and results have not yet been posted.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HRC0202's landscape · Trovocabtagene autoleucel (C-CAR088)'s landscape